$CMND +61% Premarket 🚀 🔹 Clearmind Medicine is ripping after Johns Hopkins IRB approval to advance its CMND-100 Phase I/II trial 📈 🔹 CMND-100 targets alcoho

$CMND +61% Premarket 🚀 🔹 Clearmind Medicine is ripping after Johns Hopkins IRB approval to advance its CMND-100 Phase I/II trial 📈 🔹 CMND-100 targets alcohol use disorder, giving this a major clinical-stage biotech catalyst 💊 🔹 Company is focused on psychedelic-derived treatments for addiction…